“Exon-Skipping Drugs for Duchenne Muscular Dystrophy: A Critical Test for FDA Rare Disease ” — what this page in the network covers. A new class of exon-skipping therapies for Duchenne muscular dystrophy is raising questions about access and regulatory priorities. Currently, only a small subset of patients with specific genetic mutations can benefit from these drugs, leaving many families without options. The situation highlights the FDA's stated commitment to advancing rare disease treatments, but also exposes the challenges of developing therapies for ultra-rare subgroups. Key players include drugmakers Sarepta Therapeutics and NS Pharma, whose approved drugs target different exon mutations.
With an estimated 15,000 to 20,000 people in the U.S. living with Duchenne, the debate over accelerated approval and real-world evidence is intensifying. As regulators weigh next steps, patient advocates argue that broader access could accelerate learning about long-term safety and efficacy. The full version stays on the original page, which this listing opens directly.